Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 135

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 135
---
 third-party approvals and the fulfillment of customary closing conditions. There is no certainty
and DiamiR can provide no assurances that the parties will successfully negotiate and enter into a definitive agreement, or that the DiamiR
merger will be consummated on the terms or timeframe currently contemplated, or at all. If the DiamiR merger is not completed as contemplated,
DiamiR could suffer adverse consequences, including the loss of investor confidence, volatility and a significant decrease in the market
prices of its securities and reputational harm. In addition, any delay in completing the merger could cause DiamiR not to realize some
or all of the benefits that it expects to achieve if the merger is successfully completed within the expected timeframe. There is no guarantee
that DiamiR will find an alternative entity with which to merge.

If researchers, clinicians and healthcare administrators do not adopt DiamiR’s screening and diagnostic products, DiamiR will not achieve future sales growth.

DiamiR’s business model
is heavily reliant on the adoption of its products by researchers, clinicians, and healthcare administrators (“Industry Advocates”).
These professionals play a critical role in the healthcare ecosystem, influencing both the acceptance and the utilization of new medical
technologies. A failure to secure and maintain adoption among these groups poses a significant risk to DiamiR’s operations. New
products frequently are subject of slow adoption by healthcare specialists partly due to perceived liability risks and the uncertainty
of third-party reimbursement. It is critical to the success of DiamiR’s future sales growth that it continues to work with key opinions
leaders in the field, educate healthcare specialists about CogniMIR and other assays in development, and demonstrate the
clinical utility of its technology. If Industry Advocates do not believe in DiamiR’s products, market acceptance of its products
could fail to increase or could decrease, and its business could be harmed. Additionally, a lack of support from Industry Advocates could
reduce the rate of coverage and reimbursement by both public and private third-party payors for DiamiR’s products and services,
which may further slow the market adoption of its product by physicians, significantly reduce its ability to achieve expected revenues
and prevent DiamiR from becoming profitable. Slow adoption of DiamiR’s product by Industry Advocates would significantly reduce
its ability to achieve expected sales and could prevent DiamiR from achieving and maintaining profitability.

New product development and clinical validation involves a lengthy and complex process, and DiamiR may be unable to commercialize